Skip to Content

DTIC-Dome Side Effects

Generic Name: dacarbazine

Note: This document contains side effect information about dacarbazine. Some of the dosage forms listed on this page may not apply to the brand name DTIC-Dome.

For the Consumer

Applies to dacarbazine: powder for solution, powder for suspension

Along with its needed effects, dacarbazine (the active ingredient contained in DTIC-Dome) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer, such as leukemia. Discuss these possible effects with your doctor.

Check with your doctor immediately if any of the following side effects occur while taking dacarbazine:

More common
  • Redness, pain, or swelling at place of injection
Less common
  • Black, tarry stools
  • blood in urine or stools
  • cough or hoarseness, accompanied by fever or chills
  • fever or chills
  • lower back or side pain, accompanied by fever or chills
  • painful or difficult urination, accompanied by fever or chills
  • pinpoint red spots on skin
  • unusual bleeding or bruising
  • Shortness of breath
  • stomach pain
  • swelling of face
  • yellow eyes or skin

Check with your doctor as soon as possible if any of the following side effects occur while taking dacarbazine:

  • Sores in mouth and on lips

Some side effects of dacarbazine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Loss of appetite
  • nausea or vomiting (should lessen after 1 or 2 days)
Less common
  • Feelings of uneasiness
  • flushing of face
  • muscle pain
  • numbness of face

This medicine may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.

After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:

  • Black, tarry stools
  • blood in urine or stools
  • cough or hoarseness, accompanied by fever or chills
  • fever or chills
  • lower back or side pain, accompanied by fever or chills
  • painful or difficult urination, accompanied by fever or chills
  • pinpoint red spots on skin
  • unusual bleeding or bruising

For Healthcare Professionals

Applies to dacarbazine: intravenous powder for injection


Hematologic side effects may be delayed for 2 to 4 weeks after dosage administration.[Ref]

Hematologic side effects including hematopoietic depression (involving primarily the leukocytes and platelets) are the most commonly reported toxicity. Severe cases of leukopenia and thrombocytopenia resulting in fatality have been reported. Anemia has also been reported.[Ref]


Gastrointestinal side effects including anorexia, nausea, and vomiting have been reported frequently. Diarrhea has rarely been reported.[Ref]

Anorexia, nausea, and vomiting may begin within 1 to 12 hours of dosage administration. Over 90% of patients are affected within the first few doses. Intractable nausea and vomiting have rarely necessitated discontinuation of therapy. Vomiting has been reported to last for 1 to 2 hours and be incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Some clinicians have recommended the use of serotonin receptor antagonist to control the nausea and vomiting. The rapid toleration of nausea and vomiting may suggest a central nervous system mechanism. Usually these symptoms subside after the first day or two. In a trial of high-dose dacarbazine, of 28 dosages equal to or greater than 1,380 mg/m2, all caused nausea and vomiting. At 1,380 mg/m2, 12 of 14 patients experienced diarrhea. Of 13 dosages greater than 1,380 mg/m2, all caused diarrhea.[Ref]


The manufacturer states that hepatic toxicity has occurred primarily when dacarbazine (the active ingredient contained in DTIC-Dome) has been administered concomitantly with other antineoplastic agents.

In one study, fatal massive hepatic necrosis with widespread thrombotic occlusion of the small hepatic veins developed in two of 68 patients (3%). The study notes 13 similar reactions in patients receiving dacarbazine as single agent therapy to have been reported in the literature. Hepatic toxicity may be delayed.[Ref]

Hepatic side effects including hepatic vein thrombosis and fatal hepatocellular necrosis have been reported (0.01%).[Ref]


Because the hypotension was reversible by either stopping the infusion or administration of calcium chloride, it has been suggested that the citric acid preservative may have been the cause of the hypotension.[Ref]

Cardiovascular side effects including dose-limiting hypotension have been reported during high dose therapy.[Ref]


Hypersensitivity side effects including anaphylaxis have been reported.[Ref]


Dermatologic side effects including erythematous and urticarial rashes, facial flushing, phototoxic dermatitis, facial paresthesia, alopecia, facial flushing, and photosensitivity have been reported.[Ref]

Ten cases of photosensitivity have been reported.[Ref]


The influenza-like syndrome usually occurs after large single doses, and may occur with successive treatments. Onset may occur after approximately 7 days and symptoms generally resolve after 1 to 3 weeks.[Ref]

Other side effects including an influenza-like syndrome (fever to 39 degrees Celsius, myalgias, and malaise) have been reported. Metallic taste has also been reported.[Ref]


Local side effects including extravasation of the drug subcutaneously during intravenous administration have been reported to have resulted in local pain (occasionally severe), burning sensation, irritation and tissue damage.[Ref]


Oncologic side effects have been reported in animal studies.[Ref]


1. Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ "Phase I trial of intermittent high-dose dacarbazine." Cancer Treat Rep 68 (1984): 499-504

2. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.

3. "Multum Information Services, Inc. Expert Review Panel"

4. Feaux de Lacroix W, Runne U, Hauk H, Doepfmer K, Groth W, Wacker D "Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment." Cancer Treat Rep 67 (1983): 779-84

5. Sutherland CM, Krementz ET "Hepatic toxicity of DTIC." Cancer Treat Rep 65 (1981): 321-2

6. Marsh JC "Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication." Hepatology 9 (1989): 790-2

7. Mudipalli A, Srikanth NS, Maccubbin AE, Gurtoo HL "Mutations induced by cytochrome P-450-activated dacarbazine (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 35 (1994): a6811994

8. Mudipalli A, Nadadur SS, Maccubbin AE, Gurtoo HL "Mutations induced by dacarbazine activated with cytochrome P-450." Mutat Res 327 (1995): 113-20

Some side effects of DTIC-Dome may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.